Glenmark Pharmaceuticals Ltd share price was down by -0.21% from the previous closing price of ₹1,403.10. Who are peers of Glenmark Pharmaceuticals Ltd? The peers of Glenmark Pharmaceuticals Ltd ...

Stock Market Today: Glenmark Pharmaceuticals share price gained more than 5% during intraday trades on Monday post Q3 Results that were declared after the market Hours. Glenmark Pharmaceuticals ...

This new product will be available in the strength of 6 gm/30 mL (200 mg/mL) single-dose vials in the US market, marking an expansion of Glenmark’s injectable portfolio.

Alivus Life Sciences Ltd share price was up by 0.64% from the previous closing price of ₹1,017.45. Who are peers of Alivus Life Sciences Ltd? The peers of Alivus Life Sciences Ltd are Sun ...

is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM ...

The revenue from operations at Glenmark Pharma during Q3FY25 also marked a 35.1 per cent year-on-year (YoY) rise to Rs 3,387.6 crore, coming in higher-than-estimates of Rs 3,350 crore. Glenmark Europe ...

Glenmark Pharmaceuticals reported a net profit of Rs 348 crore for Q3FY25, a significant turnaround from a Rs 351 crore loss in the previous year. Revenue increased by 35% YoY to Rs 3,388 crore.

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic ...

Glenmark Pharmaceuticals Inc. USA has acquired and launched Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose ...

Glenmark Therapeutics Inc., USA announced today the launch of its Polyethylene Glycol 3350, Powder for Solution, an over-the-counter laxative that will compete directly with Bayer’s MiraLAX.